Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus SABR in EGFR mutant NSCLC
NCT03667820Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2018
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by UT Southwestern Medical Center. Primary endpoint: Progression-Free Survival up to 300 weeks. Started Sep 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03667820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667820.